Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Target Price at $10.86

Shares of Personalis, Inc. (NASDAQ:PSNL) have received an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.8571.

PSNL has been the subject of a number of recent analyst reports. HC Wainwright increased their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Guggenheim lifted their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Personalis in a report on Wednesday, November 5th.

Personalis Price Performance

Shares of PSNL stock opened at $8.28 on Friday. The stock’s fifty day simple moving average is $8.78 and its 200 day simple moving average is $7.82. Personalis has a one year low of $2.83 and a one year high of $11.50. The firm has a market cap of $735.26 million, a price-to-earnings ratio of -9.41 and a beta of 1.98.

Insider Buying and Selling at Personalis

In related news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new position in shares of Personalis during the second quarter worth approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the fourth quarter valued at approximately $31,000. Ameritas Investment Partners Inc. bought a new position in Personalis in the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after buying an additional 3,592 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.